U.S. markets closed
  • S&P Futures

    4,155.00
    -28.50 (-0.68%)
     
  • Dow Futures

    34,557.00
    -111.00 (-0.32%)
     
  • Nasdaq Futures

    13,197.50
    -159.25 (-1.19%)
     
  • Russell 2000 Futures

    2,181.30
    -28.30 (-1.28%)
     
  • Crude Oil

    64.60
    -0.32 (-0.49%)
     
  • Gold

    1,837.40
    -0.20 (-0.01%)
     
  • Silver

    27.42
    -0.07 (-0.26%)
     
  • EUR/USD

    1.2139
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.6020
    +0.0250 (+1.59%)
     
  • Vix

    19.66
    +2.97 (+17.80%)
     
  • GBP/USD

    1.4116
    -0.0005 (-0.04%)
     
  • USD/JPY

    108.9160
    +0.0750 (+0.07%)
     
  • BTC-USD

    55,306.09
    -3,573.02 (-6.07%)
     
  • CMC Crypto 200

    1,454.90
    -106.40 (-6.81%)
     
  • FTSE 100

    7,123.68
    -6.03 (-0.08%)
     
  • Nikkei 225

    28,734.06
    -784.28 (-2.66%)
     

For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51

Manikandan Raman

Goldman Sachs launched coverage of Sarepta Therapeutics Inc (NASDAQ: SRPT) with a Neutral rating as it prefers to take a “wait and watch” approach on the launch of Exondys 51, which has been granted accelerated approval for Duchenne Muscular Dystrophy (DMD).

“GS/ consensus estimates project Exondys 51 will have one of the steepest launch curves vs. historical IV/SO orphan drugs (excludes orals Orkambi/ Kalydeco). We therefore take a watch and wait approach to the launch,” Goldman analysts wrote in a note.

Goldman says it would become more constructive on the stock once it gets further clarity on net price, payor outlook and physician adoption. As of now, six out of large seven payors have opted to reimburse the drug and KOL’s anticipate to use given this is the only approved therapy.

“We model for Exondys 51 and follow-ons SRP-4045 and SRP-4053 (+16% of DMD genotypes) with 2025 WW peak sales of $1.6bn,” the analysts continued.

The brokerage expects a gradual launch due to payor coverage, patient genotyping and securing of IV/infusion sites, followed by a sales inflection after 3-6+ months.

“Our physician diligence suggests significant awareness of Exondys 51 among neuromuscular specialists, and we expect widespread uptake in ambulatory patients (-50% of DMD) and more restricted use in non-ambulatory patients,” the analysts added.

Further, the analysts suggest that the Sarepta’s implied net price guidance of 55 percent gross-to-net discount (25kg/patient) could prove conservative.

At last check, shares of Sarepta fell 2.33 percent to $29.29. Goldman has a price target of $40, implying a potential upside of 36 percent.

Latest Ratings for SRPT

Dec 2016

Goldman Sachs

Initiates Coverage On

Neutral

Oct 2016

Morgan Stanley

Initiates Coverage On

Equal-Weight

Oct 2016

Credit Suisse

Initiates Coverage On

Outperform

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

See more from Benzinga

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.